PRLD Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
5.7M
+24.5%
4.6M
-18.8%
5.6M
-13.2%
6.5M
0
Cost of Revenue
0
0
0
0
0
Gross Profit
5.7M
+24.5%
4.6M
-18.8%
5.6M
-13.2%
6.5M
0
Operating Expenses
21.2M
+12.8%
18.8M
-18.4%
23.0M
-14.6%
26.9M
-16.4%
32.2M
R&D
16.1M
+18.6%
13.6M
-24.4%
18.0M
-17.1%
21.7M
-15.8%
25.8M
SG&A
5.0M
-2.5%
5.2M
+3.2%
5.0M
-4.1%
5.2M
-18.7%
6.4M
Operating Income
-15454000
-9.0%
-14177000
+18.3%
-17348000
+15.0%
-20418000
+36.6%
-32194000
EBITDA
-15101000
-9.5%
-13786000
+18.6%
-16930000
+15.3%
-19993000
+37.1%
-31761000
Net Income
-13921000
-34.0%
-10385000
+36.9%
-16457000
+16.6%
-19725000
+36.8%
-31231000
EPS (Basic)
$-0.14
-7.7%
$-0.13
+38.1%
$-0.21
+19.2%
$-0.26
+36.6%
$-0.41
EPS (Diluted)
$-0.14
-7.7%
$-0.13
+38.1%
$-0.21
+19.2%
$-0.26
+36.6%
$-0.41
Shares (Diluted)
98.4M
+19.2%
82.5M
+3.5%
79.7M
+4.7%
76.1M
+0.2%
76.0M
Prelude Therapeutics (PRLD) โ€” Financials